Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

BTK

  • Jasper Rip
  • Rudi W. Hendriks
  • Odilia B. J. Corneth
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101553

Synonyms

Historical Background

Bruton’s tyrosine kinase (BTK), a member of the Tec family of nonreceptor kinases, is expressed in all hematopoietic cells except T and NK cells and functions in many different signaling pathways (Table 1). It functions as a crucial signaling molecule downstream of many receptors, including the B cell receptor (BCR) on B lymphocytes. Loss-of-function mutations in the Btk gene were shown to drive X-linked agammaglobulinemia (XLA), an inherited immunodeficiency disease marked by near absence of peripheral B cells and circulating immunoglobulins (Ig), first described by Dr. O.C. Bruton in 1952. Since this discovery, many striking findings have contributed to our understanding of the role of Btk in B cell development and function (Fig. 1).
BTK, Table 1

Btk is involved in signaling pathways downstream of various receptors on different immune cell types

Receptor...

This is a preview of subscription content, log in to check access.

References

  1. Amsbaugh DF, Hansen CT, Prescott B, Stashak PW, Barthold DR, Baker PJ. Genetic control of the antibody response to type 3 pneumococcal polysaccharide in mice. I. Evidence that an X-linked gene plays a decisive role in determining responsiveness. J Exp Med. 1972;136:931–49.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Aoki Y, Isselbacher KJ, Pillai S. Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells. Proc Natl Acad Sci USA. 1994;91:10606–9.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722–8.PubMedGoogle Scholar
  4. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.  https://doi.org/10.1056/NEJMoa1215637.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–32.  https://doi.org/10.1056/NEJMoa1509981.CrossRefPubMedCentralPubMedGoogle Scholar
  6. Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014;4:1022–35.  https://doi.org/10.1158/2159-8290. CD-14-0098 [pii]CrossRefPubMedPubMedCentralGoogle Scholar
  7. Corneth OB, Klein Wolterink RG, Hendriks RW. BTK signaling in B cell differentiation and autoimmunity. Curr Top Microbiol Immunol. 2016;393:67–105.  https://doi.org/10.1007/82_2015_478.CrossRefPubMedCentralPubMedGoogle Scholar
  8. de Gorter DJ, Beuling EA, Kersseboom R, Middendorp S, van Gils JM, Hendriks RW, et al. Bruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity. 2007;26:93–104.PubMedPubMedCentralCrossRefGoogle Scholar
  9. de Weers M, Brouns GS, Hinshelwood S, Kinnon C, Schuurman RK, Hendriks RW, et al. B-cell antigen receptor stimulation activates the human Bruton’s tyrosine kinase, which is deficient in X-linked agammaglobulinemia. J Biol Chem. 1994;269:23857–60.PubMedCentralPubMedGoogle Scholar
  10. Hendriks RW, de Bruijn MF, Maas A, Dingjan GM, Karis A, Grosveld F. Inactivation of Btk by insertion of lacZ reveals defects in B cell development only past the pre-B cell stage. EMBO J. 1996;15:4862–72.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14:219–32.  https://doi.org/10.1038/nrc3702.CrossRefPubMedCentralPubMedGoogle Scholar
  12. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075–80.  https://doi.org/10.1073/pnas.1004594107.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Pearl ER, Vogler LB, Okos AJ, Crist WM, Lawton 3rd AR, Cooper MD. B lymphocyte precursors in human bone marrow: an analysis of normal individuals and patients with antibody-deficiency states. J Immunol. 1978;120:1169–75.PubMedCentralPubMedGoogle Scholar
  14. Rawlings DJ, Witte ON. The Btk subfamily of cytoplasmic tyrosine kinases: structure, regulation and function. Semin Immunol. 1995;7:237–46.  https://doi.org/10.1006/smim.1995.0028.CrossRefPubMedCentralPubMedGoogle Scholar
  15. Rawlings DJ, Schwartz MA, Jackson SW, Meyer-Bahlburg A. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat Rev Immunol. 2012;12:282–94.  https://doi.org/10.1038/nri3190.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72:279–90.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Tsukada S, Simon MI, Witte ON, Katz A. Binding of beta gamma subunits of heterotrimeric G proteins to the PH domain of Bruton tyrosine kinase. Proc Natl Acad Sci USA. 1994;91:11256–60.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361:226–33.  https://doi.org/10.1038/361226a0.CrossRefPubMedCentralPubMedGoogle Scholar
  19. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16.  https://doi.org/10.1056/NEJMoa1306220.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286–94.  https://doi.org/10.1056/NEJMoa1400029.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Jasper Rip
    • 1
  • Rudi W. Hendriks
    • 1
  • Odilia B. J. Corneth
    • 1
  1. 1.Department of Pulmonary MedicineErasmus Medical Center RotterdamRotterdamThe Netherlands